|
|
抗纤维化药物治疗新冠肺炎后肺纤维化的研究进展
|
Abstract:
截至2023年5月5日，世界卫生组织已宣布由严重急性呼吸系统综合征冠状病毒2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)感染引起的新型冠状病毒肺炎(coronavirus disease-19, COVID-19)不再构成国际关注的突发公共卫生事件，但至今为止，人类对于日趋出现的新冠肺炎呼吸道后遗症的诊治仍处于探索阶段。其中，可能会发生造成永久性肺损伤的肺纤维化由于其在重症COVID-19幸存者中的高发生率引发关注。肺纤维化(pulmonary fibrosis, PF)是一种慢性进行性肺部疾病，通常会造成肺部的持续性结构破坏和呼吸衰竭。本文结合国内外最新文献，对抗纤维化药物治疗新冠肺炎导致的PF进行综述，旨在更好地指导相关治疗。
As of May 5, 2023, the World Health Organization has announced that coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection will no longer constitute a public health emergency of international concern, but so far, the diagnosis and treatment of the respiratory sequelae of emerging COVID-19 are still in the exploratory stage. Among them, pulmonary fibrosis, which may cause permanent lung injury, has attracted attention due to its high incidence in survivors of severe COVID-19. Pulmonary Fibrosis (PF) is a chronic progressive lung disease, which usually causes persistent structural destruction of the lungs and respiratory failure. This article reviews the latest literature at home and abroad on the treatment of PF caused by COVID-19 with antifibrotic drugs, in order to better guide the related treatment.
| [1] | Atabati1, E., Dehghani-Samani, A. and Gholamreza, S. (2020) Association of COVID-19 and Other Viral Infections with Interstitial Lung Diseases, Pulmonary Fibrosis, and Pulmonary Hypertension: A Narrative Review. Canadian Journal of Respiratory Therapy, 56, 70-78. https://doi.org/10.29390/cjrt-2020-021 |
| [2] | Huntley, C.C., Patel, K., Bil Bushra, S., Mobeen, F., Armitage, M.N., Pye, A., et al. (2022) Pulmonary Function Test and Computed Tomography Features during Follow-Up after SARS, MERS and COVID-19: A Systematic Review and Meta-Analysis. ERJ Open Research, 8, 00056-2022. https://doi.org/10.1183/23120541.00056-2022 |
| [3] | 管汉雄, 熊颖, 申楠茜, 等. 新型冠状病毒肺炎(COVID-19)临床影像学特征[J]. 放射学实践, 2020(2): 125-130. |
| [4] | Iqbal, N., Khanum, I., Kazi, M.A.I., Riaz, S.U., Khawaja, U.A., Awan, S., et al. (2022) Post COVID-19 Sequelae of the Respiratory System. A Single Center Experience Reporting the Compromise of the Airway, Alveolar and Vascular Components. Monaldi Archives for Chest Disease, 93. https://doi.org/10.4081/monaldi.2022.2412 |
| [5] | Li, X., Shen, C., Wang, L., Majumder, S., Zhang, D., Deen, M.J., et al. (2021) Pulmonary Fibrosis and Its Related Factors in Discharged Patients with New Corona Virus Pneumonia: A Cohort Study. Respiratory Research, 22, Article No. 203. https://doi.org/10.1186/s12931-021-01798-6 |
| [6] | Luger, A.K., Sonnweber, T., Gruber, L., Schwabl, C., Cima, K., Tymoszuk, P., et al. (2022) Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The COVID Study. Radiology, 304, 462-470. https://doi.org/10.1148/radiol.211670 |
| [7] | Ribeiro Carvalho, C.R., Lamas, C.D.A., Visani de Luna, L.A., Chate, R.C., Salge, J.M., Yamada Sawamura, M.V., et al. (2024) Post-COVID-19 Respiratory Sequelae Two Years after Hospitalization: An Ambidirectional Study. The Lancet Regional Health—Americas, 33, Article 100733. https://doi.org/10.1016/j.lana.2024.100733 |
| [8] | Babar, M., Jamil, H., Mehta, N., Moutwakil, A. and Duong, T.Q. (2024) Short and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis. Diagnostics, 14, Article 621. https://doi.org/10.3390/diagnostics14060621 |
| [9] | Cha, M.J., Solomon, J.J., Lee, J.E., Choi, H., Chae, K.J., Lee, K.S., et al. (2024) Chronic Lung Injury after COVID-19 Pneumonia: Clinical, Radiologic, and Histopathologic Perspectives. Radiology, 310, e231643. https://doi.org/10.1148/radiol.231643 |
| [10] | Shen, H., Zhang, N., Liu, Y., Yang, X., He, Y., Li, Q., et al. (2022) The Interaction between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Frontiers in Pharmacology, 12, Article 805535. https://doi.org/10.3389/fphar.2021.805535 |
| [11] | 中国研究型医院学会呼吸病学专业委员会, 北京中西医结合学会呼吸病分会. 新型冠状病毒感染引起的肺间质病变诊断和治疗专家建议[J]. 中华结核和呼吸杂志, 2020, 43(10): 827-833. |
| [12] | 裴飞, 吴健锋. 重症肺炎与炎症风暴: 共识与争议[J]. 中国实用内科杂志, 2022, 42(3): 182-185. |
| [13] | Morganstein, T., Haidar, Z., Trivlidis, J., Azuelos, I., Huang, M.J., Eidelman, D.H., et al. (2021) Involvement of the ACE2/Ang-(1–7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19. International Journal of Molecular Sciences, 22, Article 12955. https://doi.org/10.3390/ijms222312955 |
| [14] | 赵亚萍, 马辉, 曹洁. 新型冠状病毒肺炎潜在的发病机制及间充质干细胞治疗作用的研究进展[J]. 天津医药, 2020, 48(10): 920-924. |
| [15] | Mohammadi, A., Balan, I., Yadav, S., Matos, W.F., Kharawala, A., Gaddam, M., et al. (2022) Post-COVID-19 Pulmonary Fibrosis. Cureus, 14, e22770. https://doi.org/10.7759/cureus.22770 |
| [16] | Li, Y., Wu, J., Wang, S., Li, X., Zhou, J., Huang, B., et al. (2020) Progression to Fibrosing Diffuse Alveolar Damage in a Series of 30 Minimally Invasive Autopsies with COVID-19 Pneumonia in Wuhan, China. Histopathology, 78, 542-555. https://doi.org/10.1111/his.14249 |
| [17] | Myall, K.J., Mukherjee, B., Castanheira, A.M., Lam, J.L., Benedetti, G., Mak, S.M., et al. (2021) Persistent Post-COVID-19 Interstitial Lung Disease. an Observational Study of Corticosteroid Treatment. Annals of the American Thoracic Society, 18, 799-806. https://doi.org/10.1513/annalsats.202008-1002oc |
| [18] | Mizera, J., Genzor, S., Sova, M., Stanke, L., Burget, R., Jakubec, P., et al. (2024) The Effectiveness of Glucocorticoid Treatment in Post-COVID-19 Pulmonary Involvement. Pneumonia, 16, Article No. 2. https://doi.org/10.1186/s41479-023-00123-7 |
| [19] | Gül, S., Demirkol, B., Eren, R., Nuri Baydili, K., Babaoğlu Elkhatroushi, B., Ulusan, Ş.N., et al. (2023) The Role of Immunosuppressive Therapy in Post-COVID-19 Interstitial Lung Disease. European Respiratory Journal, 62, PA4591. https://doi.org/10.1183/13993003.congress-2023.pa4591 |
| [20] | Wu, J., Chen, L., Qin, C., Huo, F., Liang, X., Yang, X., et al. (2022) CD147 Contributes to SARS-CoV-2-Induced Pulmonary Fibrosis. Signal Transduction and Targeted Therapy, 7, Article No. 382. https://doi.org/10.1038/s41392-022-01230-5 |
| [21] | Lan, Y., Cheng, M., Ji, H., Bi, Y., Han, Y., Yang, C., et al. (2022) Melatonin Ameliorates Bleomycin-Induced Pulmonary Fibrosis via Activating NRF2 and Inhibiting Galectin-3 Expression. Acta Pharmacologica Sinica, 44, 1029-1037. https://doi.org/10.1038/s41401-022-01018-x |
| [22] | 中华人民共和国国家卫生健康委员会办公厅、中医药局综合司. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[EB/OL]. https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm, 2023-01-05. |
| [23] | Gordon, A.C., Angus, D.C. and Derde, L.P.G. (2021) Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19 Reply. New England Journal of Medicine, 385, 1147-1149. |
| [24] | 王杰, 吴雪丰, 徐强. 新型冠状病毒肺炎所致肺纤维化: 从发生机制到药物治疗[J]. 中国药理学通报, 2023, 39(4): 622-626. |
| [25] | 李丹瑞. 抗纤维化药物对新冠肺炎后肺纤维化的作用观察[D]: [硕士学位论文]. 长春: 吉林大学, 2024. |
| [26] | 芮艳, 黄礼年, 刘霞, 等. 吡非尼酮对新冠后肺纤维患者的抗纤维化作用研究[J]. 齐齐哈尔医学院学报, 2024, 45(19): 1818-1821. |
| [27] | 程炜炜, 王妮妮, 张青, 等. 吡非尼酮对重型新型冠状病毒肺炎患者肺纤维化的治疗作用[J]. 浙江临床医学, 2024, 26(4): 509-511. |
| [28] | Kerget, B., Cil, G., Araz, O., Alper, F. and Akgun, M. (2022) When and How Important Is Anti-Fibrotic Therapy in the Post-COVID-19 Period? Bratislava Medical Journal, 123, 653-6958. https://doi.org/10.4149/bll_2022_105 |
| [29] | Boshra, M.S., Abou Warda, A.E., Sayed, M.A., Elkomy, M.H., Alotaibi, N.H., Mohsen, M., et al. (2022) Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm. Healthcare, 10, Article 2387. https://doi.org/10.3390/healthcare10122387 |
| [30] | Acat, M., Yildiz Gulhan, P., Oner, S. and Turan, M.K. (2021) Comparison of Pirfenidone and Corticosteroid Treatments at the COVID-19 Pneumonia with the Guide of Artificial Intelligence Supported Thoracic Computed Tomography. International Journal of Clinical Practice, 75. https://doi.org/10.1111/ijcp.14961 |
| [31] | Sansores, R.H., Ramírez-Venegas, A., Montiel-Lopez, F., Domínguez-Arellano, S., Alva-Lopez, L.F., Falfán-Valencia, R., et al. (2023) Prolonged-release Pirfenidone in Patients with Pulmonary Fibrosis as a Phenotype of Post-Acute Sequelae of COVID-19 Pneumonia. Safety and Efficacy. Respiratory Medicine, 217, Article 107362. https://doi.org/10.1016/j.rmed.2023.107362 |
| [32] | Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K.E., Stowasser, S., et al. (2015) Mode of Action of Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. European Respiratory Journal, 45, 1434-1445. https://doi.org/10.1183/09031936.00174914 |
| [33] | Umemura, Y., Mitsuyama, Y., Minami, K., Nishida, T., Watanabe, A., Okada, N., et al. (2021) Efficacy and Safety of Nintedanib for Pulmonary Fibrosis in Severe Pneumonia Induced by COVID-19: An Interventional Study. International Journal of Infectious Diseases, 108, 454-460. https://doi.org/10.1016/j.ijid.2021.05.055 |
| [34] | Bussolari, C., Palumbo, D., Fominsky, E., Nardelli, P., De Lorenzo, R., Vitali, G., et al. (2021) Case Report: Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019. Frontiers in Medicine, 8, Article 766486. https://doi.org/10.3389/fmed.2021.766486 |
| [35] | Saiphoklang, N., Patanayindee, P. and Ruchiwit, P. (2022) The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. Critical Care Research and Practice, 2022, 1-7. https://doi.org/10.1155/2022/9972846 |
| [36] | 吕紫薇, 黄凯, 甘文华, 等. 吡非尼酮和尼达尼布抑制博来霉素诱导的小鼠肺纤维化药效比较[J]. 中国病理生理杂志, 2020, 36(1): 112-118. |
| [37] | Singh, P., Behera, D., Gupta, S., Deep, A., Priyadarshini, S. and Padhan, P. (2022) Nintedanib vs Pirfenidone in the Management of COVID-19 Lung Fibrosis: A Single-Centre Study. Journal of the Royal College of Physicians of Edinburgh, 52, 100-104. https://doi.org/10.1177/14782715221103402 |
| [38] | Kerget, B., Çil, G., Araz, Ö., Alper, F. and Akgün, M. (2023) Comparison of Two Antifibrotic Treatments for Lung Fibrosis in Post-COVID-19 Syndrome: A Randomized, Prospective Study. Medicina Clínica, 160, 525-530. https://doi.org/10.1016/j.medcli.2022.12.021 |
